Diagnostic and therapeutic uses of inhaled nitric oxide in neonatal Ebstein's anomaly.
Atz
Andrew M
AM
Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA. atzam@musc.edu
Munoz
Ricardo A
RA
Adatia
Ian
I
Wessel
David L
DL
D000280:Administration, Inhalation; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D006348:Cardiac Surgical Procedures; D004437:Ebstein Anomaly / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D004452:Echocardiography; D005500:Follow-Up Studies; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007229:Infant Welfare; D007231:Infant, Newborn; D015997:Neonatal Screening; D009569:Nitric Oxide / Q000627:therapeutic use*; D009585:Nitrogen Dioxide / Q000097:blood; D010100:Oxygen / Q000097:blood; D011458:Prostaglandins E / Q000627:therapeutic use; D018633:Pulmonary Atresia / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D011652:Pulmonary Circulation / Q000502:physiology; D012720:Severity of Illness Index; D016019:Survival Analysis; D016896:Treatment Outcome
D015415:Biomarkers; D011458:Prostaglandins E; D009569:Nitric Oxide; D009585:Nitrogen Dioxide; D010100:Oxygen